Results 21 to 30 of about 174,156 (175)

B cell signalling pathways—New targets for precision medicine in chronic lymphocytic leukaemia

Scandinavian Journal of Immunology, Volume 92, Issue 5, November 2020., 2020
Abstract The B cell receptor (BCR) is a master regulator of B cells, controlling cellular processes such as proliferation, migration and survival. Cell signalling downstream of the BCR is aberrantly activated in the B cell malignancy chronic lymphocytic leukaemia (CLL), supporting the pathophysiology of the disease.
Sigrid S. Skånland, Linda Karlsen, Kjetil Taskén   +2 more
wiley   +1 more source

Inhibition of Bruton's TK regulates macrophage NF‐κB and NLRP3 inflammasome activation in metabolic inflammation

British Journal of Pharmacology, Volume 177, Issue 19, Page 4416-4432, October 2020., 2020
Background and Purpose There are no medications currently available to treat metabolic inflammation. Bruton's tyrosine kinase (BTK) is highly expressed in monocytes and macrophages and regulates NF‐κB and NLRP3 inflammasome activity; both propagate metabolic inflammation in diet‐induced obesity.
Gareth S.D. Purvis, Massimo Collino, Haidee Aranda‐Tavio, Fausto Chiazza, Caroline E. O'Riordan, Lynda Zeboudj, Shireen Mohammad, Debora Collotta, Roberta Verta, Nicolas E.S. Guisot, Peter Bunyard, Magdi M. Yaqoob, David R. Greaves, Christoph Thiemermann   +13 more
wiley   +1 more source

Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature

British Journal of Haematology, Volume 190, Issue 2, Page 185-188, July 2020., 2020
Summary SARS‐CoV‐2 infection can cause severe pneumonia (COVID‐19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS‐CoV‐2 viraemia with fatal outcome in patients after ...
Phil‐Robin Tepasse, Wali Hafezi, Mathias Lutz, Joachim Kühn, Christian Wilms, Rainer Wiewrodt, Jan Sackarnd, Martin Keller, Hartmut H. Schmidt, Richard Vollenberg   +9 more
wiley   +1 more source

Clinical characteristics and prenatal diagnosis in 22 families in Henan Province of China with X-linked agammaglobulinemia (XLA) related with Bruton’s tyrosine kinase (BTK) gene mutations.

, 2020
Background: X-linked agammaglobulinaemia (XLA) is a rare immunodeficiency disease, and the main clinical symptoms is recurrent severe infections. BTK is the main disease-causing gene, and the genetic mode is X chromosome recessive inheritance.
Shanshan Gao, Shuang Hu, H. Duan, Li Wang, X. Kong   +4 more
semanticscholar   +1 more source

Autologous non‐human primate model for safety assessment of piggyBac transposon‐mediated chimeric antigen receptor T cells on granulocyte–macrophage colony‐stimulating factor receptor

Clinical &Translational Immunology, Volume 9, Issue 11, 2020., 2020
We pre‐clinically evaluated the safety of granulocyte–macrophage colony‐stimulating factor (GMCSF) receptor (GMR)–chimeric antigen receptor (CAR) T cells. For this purpose, we used a novel immunocompetent non‐human primate (NHP) model, established using bioengineered cynomolgus T cells expressing CAR‐T molecules redirected against the GMR by piggyBac ...
Hirokazu Morokawa, Shigeki Yagyu, Aiko Hasegawa, Miyuki Tanaka, Shoji Saito, Hidemi Mochizuki, Kengo Sakamoto, Akihito Shimoi, Yozo Nakazawa   +8 more
wiley   +1 more source

Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals [PDF]

, 2016
Chemo immunotherapies for chronic lymphocytic leukemia (CLL) showed a positive impact on clinical outcome, but many patients relapsed or become refractory to the available treatments.
Facco, Monica, Frezzato, Federica, Martini, Veronica, Semenzato, Gianpietro, Severin, Filippo, Trentin, Livio, Trimarco, Valentina, Visentin, Andrea   +7 more
core   +1 more source

Atypical X-linked agammaglobulinaemia caused by a novel BTK mutation in a selective immunoglobulin M deficiency patient [PDF]

BMC Pediatrics, 2013
BackgroundX-linked agammaglobulinaemia (XLA) is the most common inherited humoural immunodeficiency disorder. Mutations in the gene coding for Bruton’s tyrosine kinase (BTK) have been identified as the cause of XLA.
A Etzioni, A Moise, A Plebani, A Sawada, A Vargas-Hernandez, A Yoshino, AK Dobbs, D Vetrie, Daw-Yang Hwang, DM Stewart, E Lopez-Granados, E Stiehm, HD Ochs, Hung-Chun Chen, HW Eijkhout, I-Fang Wang, IM Pessach, IM Pessach, J Väliaho, Jer-Ming Chang, K Maekawa, L Yel, L Yel, Lee-Moay Lim, LM Endo, M Antar, ME Conley, ME Conley, ME Conley, ME Conley, ME Conley, MF Goldstein, MF Guill, N Basile, N Shinomiya, OC Bruton, S Nonoyama, S Tsukada, SP Kwan, T Ohno, Wei-Chiao Chang, Y Minegishi, Y Minegishi, Y Minegishi   +43 more
core   +2 more sources

Role of Bruton's tyrosine kinase in B cells and malignancies [PDF]

, 2018
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primary
Dammeijer, F. (Floris), Hendriks, R.W. (Rudi), Pal Singh, S. (Simar)   +2 more
core   +3 more sources

Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib [PDF]

, 2017
The Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes increased risk of bleeding. Off-target inhibition of Tec is believed to contribute to platelet dysfunction and other side-effects of ibrutinib.
Appleby, Niamh, Bruce, David, Bye, Alex P., Desborough, Michael J., Gibbins, Jon M., Hildyard, Catherine A. T., Hughes, Craig E., Kriek, Neline, Nock, Sophie H., Sage, Tanya, Unsworth, Amanda J.   +10 more
core   +2 more sources

Future therapeutic targets in rheumatoid arthritis? [PDF]

, 2017
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. Without adequate treatment, patients with RA will develop joint deformity and progressive functional impairment.
A Balanescu, A Bilancio, A Del Prete, A Maas, AB Avci, AB Satterthwaite, AD Cook, AG Semb, AJ Fleetwood, AJ Fleetwood, AJ Mohamed, AL Bell, AL Cornish, AM Condliffe, AR Pettit, AW Lieshout van, B Ludewig, BF Nashed, BJ Jenkins, BZ Li, C Baerwald, C Meune, C Rommel, C Schindler, C Voigtlander, CA Martin, CJ Heijnen, CM Hilkens, CV Brenol, D Heijde van der, DH Solomon, DJ Rawlings, DL Bellinger, DM Nance, DS Lim, DT Patton, E Banham-Hall, E Clayton, E Feist, E Hirsch, E Martin, E Thomas, EB Lee, EC Tsark, EK Evans, F Berenbaum, F Bussolino, F Ramadani, FA Koopman, FA Koopman, FM Foster, G Hansen, GM Bell, GR Burmester, GR Burmester, H Evrengul, H Wang, Iain B. McInnes, IC Eijk van, IJ Elenkov, IK Campbell, J Askling, J Jang, J Kremer, JA Avina-Zubieta, JA Hamilton, JC Barrientos, JE Park, JM Kremer, JM Waldburger, JS Rawlings, JS Smolen, K Imada, K Okkenhaug, K Okkenhaug, K Okkenhaug, K Pavelka, K Reif, K Shuai, K Thiele, K Yamaoka, KL Winthrop, KP MacDonald, KS Nair, L Conti, L Jansson, L Senolt, L Zhang, L Zou, LC Cantley, LG Schipper, LJ Courtright, LV Borovikova, M Camps, M Dougados, M Field, M Gilliet, M Pesu, M Rosas-Ballina, M Skoberne, M Skoberne, M Soubrier, M Westman, MA Maanen van, MA Maanen van, MA Maanen van, MB Torchinsky, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Lebre, MC Lebre, MG Roncarolo, MJ Peters, MS Ahmed, MS Thomas, N Krishnamoorthy, N Sato, NJ Gullick, P Geborek, P Norman, P Sujobert, PC Heinrich, PC Taylor, Q Yang, R Fleischmann, R Fleischmann, RA Maldonado, RF Vollenhoven van, RH Straub, RM Buijs, RM Steinman, RM Steinman, S Hayer, S Kleinau, S Mukhopadhyay, S Mukhopadhyay, S Somersan, S Tsukada, SA Provan, ST Jou, T Leizer, T Li, Tommy Tsang Cheung, TR Radstake, WJ Jonge de, WN Khan, Y Ren, Y Xu, YP Goekoop-Ruiterman, Z Li, Z Pan   +154 more
core   +1 more source